Indazole compounds

Details Indazole compounds Indazole compounds

2011-08-30

2011-08-30

Saeed, Kamal (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S361500, C548S362500, C514S406000, C514S407000

Reexamination Certificate

active

08008506

ABSTRACT:
Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have β3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

REFERENCES:
patent: 2787515 (1957-04-01), Frederic et al.
patent: 4378361 (1983-03-01), Schromm et al.
patent: 5767133 (1998-06-01), Dow et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6037362 (2000-03-01), Miyoshi et al.
patent: 6172099 (2001-01-01), Miyoshi et al.
patent: 6187809 (2001-02-01), Miyoshi et al.
patent: 6353025 (2002-03-01), Tamai et al.
patent: 6495701 (2002-12-01), Matsubara et al.
patent: 6545053 (2003-04-01), Miyoshi et al.
patent: 6861444 (2005-03-01), Ikuta et al.
patent: 7049445 (2006-05-01), Ikuta et al.
patent: 7199147 (2007-04-01), Imazaki et al.
patent: 7217724 (2007-05-01), Ueno et al.
patent: 7271190 (2007-09-01), Miyoshi et al.
patent: 7511069 (2009-03-01), Miyoshi et al.
patent: 7598284 (2009-10-01), Miyoshi et al.
patent: 2002/0120148 (2002-08-01), Taniguchi et al.
patent: 2003/0040538 (2003-02-01), Miyoshi et al.
patent: 2003/0139475 (2003-07-01), Miyoshi et al.
patent: 2003/0191174 (2003-10-01), Ikuta et al.
patent: 2004/0053967 (2004-03-01), Hara et al.
patent: 2004/0102437 (2004-05-01), Takami et al.
patent: 2004/0127546 (2004-07-01), Ikuta et al.
patent: 2004/0138286 (2004-07-01), Imazaki et al.
patent: 2005/0020602 (2005-01-01), Miyoshi et al.
patent: 2006/0063762 (2006-03-01), Ueno et al.
patent: 2008/0015242 (2008-01-01), Miyoshi et al.
patent: 2008/0076815 (2008-03-01), Miyoshi et al.
patent: 2008/0306160 (2008-12-01), Kobayashi et al.
patent: 2009/0170826 (2009-07-01), Hagihara et al.
patent: 2010/0152265 (2010-06-01), Nakano et al.
patent: 24 29 253 (1974-06-01), None
patent: 26 51 572 (1977-06-01), None
patent: 0 008 653 (1980-03-01), None
patent: 0 023 385 (1981-02-01), None
patent: 0 171 702 (1986-02-01), None
patent: 0 238 973 (1987-03-01), None
patent: 0 455 006 (1991-04-01), None
patent: 659 737 (1995-06-01), None
patent: 1 174 425 (2000-03-01), None
patent: 1 043 308 (2000-10-01), None
patent: 1 142 883 (2001-10-01), None
patent: 1 565 080 (1976-11-01), None
patent: 55-53262 (1980-04-01), None
patent: 58-41860 (1983-03-01), None
patent: 8-165276 (1996-06-01), None
patent: 94/29290 (1994-12-01), None
patent: 95/29159 (1995-11-01), None
patent: 96/35670 (1996-11-01), None
patent: 97/25311 (1997-07-01), None
patent: 99/01431 (1999-01-01), None
patent: 99/31045 (1999-06-01), None
patent: 99/51564 (1999-10-01), None
patent: 00/35890 (2000-06-01), None
patent: 00/59287 (2000-10-01), None
patent: 00/59885 (2000-10-01), None
patent: 01/56988 (2001-08-01), None
patent: 01/83451 (2001-11-01), None
patent: 01/83452 (2001-11-01), None
patent: 01/83453 (2001-11-01), None
patent: 02/060873 (2002-08-01), None
patent: 02/074306 (2002-09-01), None
patent: 02/100833 (2002-12-01), None
patent: 03/035620 (2003-05-01), None
patent: 03/106418 (2003-12-01), None
patent: 2007/026630 (2007-03-01), None
patent: 2007/063821 (2007-06-01), None
U.S. Appl. No. 12/569,324 to Seiji Nakano et al., which was filed Sep. 29, 2009.
U.S. Appl. No. 12/608,483 to Seiji Nakano et al., which was filed Oct. 29, 2009.
Zhong et al., “α1-Adrenoceptor subtypes,” Eur. J. Phamacol., vol. 375, pp. 261-276, 1999.
Arch et al., “Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs,” Nature, vol. 309, pp. 163-165, May 1984.
Arch et al., “Prospects for β3-adrenoceptor agonists in the treatment of obesity and diabetes”, International Journal of Obesity, vol. 20, pp. 191-199, 1996.
Largis et al., “Antidiabetic and Antiobesity Effects of a Highly Selective β3-Adrenoceptor Agonist (CL 316,243)”, Drug Development Research, vol. 32, pp. 69-76, 1994.
Fisher et al., “A Selective Human β3-Adrenergic Receptor Agonist Increases Metabolic Rate in Rhesus Monkeys”, J. Clin. Invest., vol. 101, pp. 2387-2393, 1998.
Berkowitz et al., “Distribution of β3-Adrenoceptor mRNA in human tissues,” Eur. J. Phamacol., vol. 289, pp. 223-228, 1995.
Howe, “β3-Adrenergic Agonists,” Drugs of the Future, vol. 18, No. 6, pp. 529-549, 1993.
De Ponti et al., “Functional evidence for the presence of β3-adrenoceptors in the guinea pig common bile duct and colon,” Pharmacology, vol. 51, pp. 288-297, 1995.
Rodriguez et al., “Evidence for the presence of β3-adrenergic receptor mRNA in the human brain,” Brain Res. Mol. Brain Res., vol. 29, No. 2, pp. 369-375, 1995.
Fujimura et al., “Expression and Possible Functional Role of the β3-Adrenoceptor in Human and Rat Detrusor Muscle”, The Journal of Urology, vol. 161, pp. 680-685, 1999.
Takeda et al., “Evidence for β3-Adrenoceptor Subtypes in Relaxation of the Human Urinary Bladder Detrusor: Analysis by Molecular Biological and Pharmacological Methods,” The Journal of Pharmacology and Experimental Therapeutics, vol. 288, pp. 1367-1373, 1999.
Bishop, “Recent advances in the discovery of α1-adrenoceptor agonists,” Current Topics in Medicinal Chemistry, vol. 7, pp. 135-145, 2007.
Michel et al., “α1-, α2- β3-adrenoceptors in the urinary bladder, urethra and prostate,” Br. J. Pharmacol., vol. 147, pp. S88-S119, 2006.
Patani et al., “Bioisosterism: A Rational Approach in Drug Design,” Chem Rev, vol. 96 (8), pp. 3147-3176, 1996.
Hoey et al., “Characteristics of cyanopindolol analogues active at the β3-adrenoceptor in rate ileum” Br. J. Pharm, vol. 119, pp. 564-568, 1996.
Cantello et al., “BRL 35135,” Drugs of the Future, vol. 16(9), pp. 797-800, 1991.
Humber et al., “Disodium (R,R)-5-[2-[[2-(3-Chlorophenyl-2-hydroxyethyl)-amino]propyl]1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A Potent β-Adreneric Agonist Virtually Specific for β3Receptors. A Promising Antidiabetic and Antiobesity Agent”, J. Med. Chem., 1992, vol. 35, pp. 3081-3084.

Affiliated with

Also associated with

Rating

Indazole compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indazole compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2650963